Papers
3
Total Citations
108
H-Index
3
About
Dr. Marilyn Leitch is a leading surgical oncologist whose research has fundamentally advanced the landscape of early-stage breast cancer treatment, particularly through the development of stereotactic partial breast irradiation (S-PBI). Her work focuses on refining radiation protocols to minimize treatment burden while maintaining excellent oncologic outcomes. Dr. Leitch’s major contributions stem from her leadership in critical phase 1 dose-escalation trials. She was instrumental in demonstrating the safety and feasibility of both 5-fraction and single-fraction S-PBI regimens after lumpectomy, as evidenced by her highly cited 2017 study (66 citations) and her 2021 multi-institutional trial (23 citations). Beyond tumor control, her research rigorously evaluates patient quality of life, notably in her 2021 study on cosmetic outcomes (19 citations), which provides essential data on post-treatment breast appearance. By pioneering these ultra-short, targeted radiation schedules, Dr. Leitch is at the forefront of de-escalating therapy, offering patients a more convenient and less toxic path to recovery without compromising survival. Her work is a cornerstone for modern, patient-centered breast cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3